Celgene Revlimid PDUFA Date Extended to January
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA pushes back the user fee date for Celgene’s myelodysplasic syndromes therapy Revlimid, originally set for Oct. 7, by three months.